Studies on the endocrine properties of a new progestational steroid 4,6-dichloro-16-methylene-17-hydroxy-4,6-pregnadiene-3,20-dione 17-acetate (MDAP).
D000311:Adrenal Glands / Q000187:drug effects; D000818:Animals; D002713:Chlorine; D002715:Chlormadinone Acetate / Q000494:pharmacology; D004336:Drug Antagonism; D004958:Estradiol / Q000494:pharmacology; D004965:Estrogen Antagonists; D005260:Female; D007664:Ketosteroids / Q000494:pharmacology; D008297:Male; D009929:Organ Size; D010053:Ovary / Q000187:drug effects; D010060:Ovulation / Q000187:drug effects; D011278:Pregnanes / Q000494:pharmacology*; D011374:Progesterone / Q000494:pharmacology; D011372:Progestins / Q000494:pharmacology*; D011467:Prostate / Q000187:drug effects; D011817:Rabbits; D051381:Rats; D012669:Seminal Vesicles / Q000187:drug effects; D013737:Testis / Q000187:drug effects; D013739:Testosterone / Q000037:antagonists & inhibitors / Q000494:pharmacology; D013950:Thymus Gland / Q000187:drug effects; D014599:Uterus / Q000187:drug effects
D004965:Estrogen Antagonists; D007664:Ketosteroids; D011278:Pregnanes; D011372:Progestins; D002715:Chlormadinone Acetate; D013739:Testosterone; D011374:Progesterone; D002713:Chlorine; D004958:Estradiol